<DOC>
	<DOCNO>NCT02462707</DOCNO>
	<brief_summary>The purpose study determine recommend Phase 2 dose PF-03084014 single-agent administration Japanese patient advance solid tumor . Pharmacokinetics overall safety profile PF-03084014 also evaluate .</brief_summary>
	<brief_title>A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histological cytological diagnosis advance solid tumor resistant standard therapy standard therapy available . Age ≥18 year . ECOG Performance Status ( PS ) must 0 1 . Adequate Bone Marrow Function Adequate Renal Function Adequate Liver Function Resolved acute effect prior therapy baseline severity Grade ≤1 Patients know brain metastasis Major surgery within 4 week start study treatment Radiation therapy within 2 week start study treatment Systemic anti cancer therapy within 2 week ( 4 week antibody ) start study treatment Previous high dose chemotherapy require stem cell rescue Prior irradiation &gt; 25 % bone marrow Prior treatment Notch signal inhibitor Known malabsorption syndrome condition may impair absorption study medication Any follow previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack symptomatic pulmonary embolism Current use anticipate need know strong and/or moderate CYP3A4 inhibitor Current use anticipate need know strong CYP3A4 inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>